Shanafelt Armen 4
4 · Surface Oncology, Inc. · Filed Apr 23, 2018
Insider Transaction Report
Form 4
Shanafelt Armen
Director10% Owner
Transactions
- Conversion
Series A Preferred Stock
2018-04-23−7,000,000→ 0 total(indirect: See Footnote)→ Common Stock (3,181,817 underlying) - Purchase
Common Stock
2018-04-23$15.00/sh+266,000$3,990,000→ 3,447,817 total(indirect: See Footnote) - Conversion
Common Stock
2018-04-23+3,181,817→ 3,181,817 total(indirect: See Footnote)
Footnotes (2)
- [F1]The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date.
- [F2]These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.